FluoroPharma Inc., a company developing breakthrough molecular imaging agents for the Positron Emission Tomography (PET) market, announced that it has entered into a licensing agreement with Massachusetts General Hospital (MGH) for the development and commercialization of agents for diagnosis and … Continue reading →

FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced commencement of Phase I clinical trials for BFPET, following institutional review board (IRB) approval of the proposed studies. The Phase I trial … Continue reading →

FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I safety results for CardioPET, the company’s lead product. The trial was designed to evaluate safety, distribution and dosimetry of … Continue reading →

FluoroPharma Inc., a company developing breakthrough cardiovascular molecular imaging agents for the Positron Emission Tomography (PET) market, announced positive Phase I safety results for CardioPET, the company’s lead product. The trial was designed to evaluate safety, distribution and dosimetry of … Continue reading →